MdxHealth (TM) : MDxHealth's Prostate Cancer Test Approved by New York State Department of Health

 MdxHealth (TM) : MDxHealth's Prostate Cancer Test Approved by New York State
                             Department of Health

IRVINE, CA, and LIEGE, BELGIUM - 8:00  AM, July 10, 2013 - MDxHealth SA  (NYSE 
Euronext: MDXH),  a leading  molecular diagnostic  company that  develops  and 
commercializes epigenetic  tests to  support the  diagnosis and  treatment  of 
cancer patients, today announced that the New York State Department of  Health 
(NYSDOH) has  certified  and  granted  approval  for  the  ConfirmMDx(TM)  for 
Prostate Cancer test. This  approval by NYSDOH  completes MDxHealth's list  of 
state licensures, allowing the Company to offer the test in all 50 states. The
ConfirmMDx for Prostate  Cancer test is  performed on tissue  obtained from  a 
previous negative  prostate biopsy  to help  distinguish patients  who have  a 
true-negative result and may forego an unnecessary repeat biopsy from those at
high risk for missed cancer.

"The NYSDOH approval  of the ConfirmMDx  for Prostate Cancer  test is a  major 
milestone for MDxHealth.  The Department's  independent technology  assessment 
for laboratory developed tests, which are also regulated at the federal level,
is widely  regarded as  the  most rigorous  review  process due  to  stringent 
quality standards. With the New  York State approval and clinical  laboratory 
license, ConfirmMDx  for Prostate  Cancer  is now  available to  patients  and 
urologists throughout  the  U.S.  This  licensure opens  one  of  our  largest 
potential domestic markets within the U.S., with an estimated 65,000  prostate 
biopsy procedures performed  annually." said Dr.  Jan Groen, MDxHealth's  CEO. 
"The NYSDOH approval completes our state licensing requirements and allows  us 
to fully execute on  our U.S. commercialization  strategy for this  clinically 
significant prostate cancer test."

About ConfirmMDx for Prostate Cancer
Over 975,000 American men receive a negative prostate biopsy result each year;
though approximately 25% of these men may still harbor occult prostate cancer.
This  well-documented  risk  of  undetected  cancer,  often  with   clinically 
significant Gleason  scores, leads  to a  high rate  of repeat  biopsies  with 
greater than  40%  of men  receiving  at least  one  repeat biopsy,  and  many 
receiving a 3^rd and 4^th biopsy. Today's gold standard diagnostic approach is
the prostate biopsy  procedure, collecting 10-12  needle core biopsy  samples; 
however this sampling represents less than 1% of a man's prostate.  ConfirmMDx 
for Prostate  Cancer is  an epigenetic  assay to  help urologists  distinguish 
patients who have a true-negative biopsy from those at risk for occult cancer.
The test is  able to detect  an epigenetic field  effect or "halo"  associated 
with the cancerization process at the DNA level. This molecular "halo"  around 
a cancer lesion can  be present despite having  a normal appearance under  the 
microscope. The test helps urologists  rule out prostate cancer-free men  from 
undergoing unnecessary repeat biopsies and rule in high-risk patients who  may 
require repeat biopsies and potential treatment.

About MDxHealth^®
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. The company  has a proprietary platform  and a strong  epigenetic 
product pipeline focused on  the development of  products for prostate,  brain 
and lung cancers. The company is  based in Irvine, California with a  European 
headquarters in Liege, Belgium. For more information visit MDxHealth's website

For more information: Mike Sinclair
Dr. Jan Groen, CEO    Halsin Partners
MDxHealth             UK: +44 20 7318 2955
US: +1 949 812 6979   Cell: +44 7968 022075
BE: +32 4 364 20 70 

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law or  regulation. This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The  MDxHealth logo,  MDxHealth, MDxHealth  Laboratories of  California, 
ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth
SA. All  other  trademarks  and  service  marks  are  the  property  of  their 
respective owners. The Company  offers its services within  the State of  New 
York as MDxHealth Laboratories of California (dba).

To access the PDF version, click here


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.